Scott Nickerson joined Moderna in May 2016 as Head of Quality accountable for all aspects of GxP Quality. In July of 2020, he transitioned to SVP US Manufacturing and Norwood Site Head to lead start up and production of COVID vaccine supply as well as clinical supplies for all programs. Scott joined Moderna from Alexion Pharmaceuticals, where he served as Vice President of Quality Assurance and Quality Control supporting biotech manufacturing for both commercial and clinical products. Scott led Quality efforts supporting commercialization of two new rare disease therapies in multiple countries. Prior to Alexion, Scott spent 14 years at Eli Lilly and Company in various roles of ascending responsibility in Quality Assurance and Quality Control supporting the commercial and clinical large molecule platform. As part of his experience at Eli Lilly, Scott spent time at Imclone Systems integrating them into the Lilly large molecule network and leading GMP quality efforts to further the late stage pipeline. Scott holds a B.S. in Chemistry from Hampden-Sydney College and an M.S. in Analytical Chemistry from the University of Arizona.